
If some of the largest U.S. employers had used biosimilar versions of a pair of widely used brand-name biologic medicines two years ago, they could have saved an average of $1.5 million and their employees would also have spent hundreds of dollars less, according to a new study.
Nearly all of the savings would have been realized if those 13 companies had relied on biosimilar versions of Remicade, a popular treatment for rheumatoid arthritis and Crohn’s disease, among other ailments. The savings, meanwhile, from biosimilar versions of Neupogen, a bone marrow stimulant for cancer patients, would have amounted to less than $18,000, on average. Spending on the two drugs represented up to 2.7% of typical annual spending on pharmaceuticals by the companies.
What is it?
STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.